Candel Common Stock Total Equity from 2010 to 2024
| CADL Stock | USD 4.51 0.06 1.31% |
Common Stock Total Equity | First Reported 2010-12-31 | Previous Quarter 328.9 K | Current Value 189.9 K | Quarterly Volatility 76.7 K |
Check Candel Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Candel Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 1.2 M, Depreciation And Amortization of 596.5 K or Interest Expense of 358.1 K, as well as many indicators such as Price To Sales Ratio of 451, Dividend Yield of 0.0 or PTB Ratio of 3.5. Candel financial statements analysis is a perfect complement when working with Candel Therapeutics Valuation or Volatility modules.
Candel | Common Stock Total Equity |
Latest Candel Therapeutics' Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Candel Therapeutics over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Candel Therapeutics' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Candel Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Candel Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 157,789 | |
| Geometric Mean | 144,931 | |
| Coefficient Of Variation | 48.62 | |
| Mean Deviation | 61,290 | |
| Median | 116,000 | |
| Standard Deviation | 76,717 | |
| Sample Variance | 5.9B | |
| Range | 212.9K | |
| R-Value | 0.69 | |
| Mean Square Error | 3.3B | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | 11,875 | |
| Total Sum of Squares | 82.4B |
Candel Common Stock Total Equity History
About Candel Therapeutics Financial Statements
Candel Therapeutics investors utilize fundamental indicators, such as Common Stock Total Equity, to predict how Candel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 328.9 K | 189.9 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Candel Therapeutics Correlation against competitors. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Revenue Per Share 0.001 | Return On Assets (0.52) | Return On Equity (4.81) |
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.